Back to top
more

Thermo Fisher Scientific (TMO)

(Delayed Data from NYSE)

$596.92 USD

596.92
2,138,161

+3.13 (0.53%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Phibro (PAHC) Q1 Earnings Surpass Estimates, Margins Up

Phibro's (PAHC) core Animal Health segment, along with strength in Nutritional Specialties and Vaccines, boosted Q1 performance despite pandemic-led business disruptions.

LHC Group (LHCG) Q3 Earnings and Revenues Beat Estimates

LHC Group's (LHCG) third-quarter results benefit from organic growth in home health as well hospice admissions.

Cardiovascular Systems' (CSII) Q1 Earnings Top Estimates

Cardiovascular Systems (CSII) registers dismal segmental revenues despite gradual recovery in business amid the pandemic.

Inogen (INGN) Stock Loses 9.2% After Delivering Loss in Q3

Inogen (INGN) saw revenue decline within its Sales segment in Q3

PRA Health (PRAH) Gains 4.3% Following Q3 Earnings Beat

PRA Health's (PRAH) Data Solutions and Clinical Research segments put up a strong performance in the third quarter.

Becton Dickinson (BDX) Earnings Surpass Estimates in Q4

Within the United States, Becton Dickinson's (BDX) Diagnostic Systems unit witnessed strong revenue growth in the fiscal fourth quarter.

DENTSPLY SIRONA (XRAY) Q3 Earnings & Revenues Beat Estimates

DENTSPLY SIRONA (XRAY) rides high on the launch of the Axeos imaging system in the third quarter.

Haemonetics (HAE) Q2 Earnings Beat Estimates, Margins Down

Haemonetics' (HAE) second-quarter fiscal 2021 results reflect impressive performance by Hospital segment despite dismal overall performance during the coronavirus-led crisis.

Insulet (PODD) Q3 Earnings & Revenues Top Estimates, View Up

Insulet's (PODD) Q3 gross margin improvement can be primarily attributed to performance of the company's U.S. manufacturing and favorable revenue mix from the shift to higher volume

Fresenius Medical (FMS) Stock Gains 5.6% on Q3 Earnings Beat

Fresenius Medical's (FMS) third-quarter earnings benefit from stable segmental performance.

Change Healthcare (CHNG) Q2 Earnings & Revenues Top Estimates

Change Healthcare's (CHNG) fiscal second-quarter results benefit from solid performance in the Network Solutions segment.

Cardinal Health (CAH) Q1 Earnings and Revenues Beat Estimates

Cardinal Health's (CAH) fiscal first-quarter results reflect strong segmental performance.

AmerisourceBergen (ABC) Q4 Earnings & Revenues Top Estimates

AmerisourceBergen's (ABC) fiscal fourth-quarter results benefit from segmental growth.

Surmodics (SRDX) Reports Q4 Loss, Revenues Beat Estimates

Surmodics (SRDX) registered revenue decline in each of its core units in the fourth quarter.

Hologic (HOLX) Q4 Earnings Surpass Estimates, Margins Rise

Hologic (HOLX) exhibited robust segmental growth in fourth-quarter fiscal 2020 driven by strong performance by the Diagnostics segment amid the coronavirus pandemic.

Thermo Fisher (TMO) Hits 52-Week High, Can the Run Continue?

Thermo Fisher (TMO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Pacific Biosciences (PACB) Loses 4.1% Post Reporting Q3 Loss

Pacific Biosciences (PACB) saw revenue decline in both its operating segments in the third quarter.

Avanos Medical (AVNS) Q3 Earnings and Revenues Top Estimates

Avanos Medical (AVNS) continued to gain from core Chronic Care segment in the third quarter.

Intersect ENT (XENT) Q3 Earnings and Revenues Beat Estimates

Intersect ENT's (XENT) PROPEL implants gain momentum and recapture procedure volume in Q3 following the drop in elective sinus procedures.

McKesson (MCK) Q2 Earnings and Revenues Surpass Estimates

McKesson's (MCK) fiscal second-quarter 2021 results benefit from strong segmental performance.

Bruker's (BRKR) Q3 Earnings & Revenues Surpass Estimates

Bruker's (BRKR) third-quarter 2020 results reflect dismal performances by two of the reporting segments and geographies due to coronavirus-led business disruptions.

Chemed's (CHE) Shares Up on Q3 Earnings and Revenue Beat

Chemed (CHE) reports solid revenue growth across key subsidiaries in third-quarter results.

Accuray (ARAY) Climbs 11.5% as Q1 Earnings Beat Estimates

Accuray (ARAY) registered growth in Service revenues in Q1.

STERIS' (STE) Earnings & Revenues Surpass Estimates in Q2

STERIS' (STE) second-quarter fiscal 2021 results reflect strong performance by the Life Sciences and the Applied Sterilization Technologies segments despite the coronavirus-led economic crisis.

Teleflex (TFX) Q3 Earnings & Revenues Beat, Decline Y/Y

Teleflex (TFX) witnesses significant sequential improvement in segmental performance on gradual recovery of the economy.